Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

被引：38

作者：

Mino-Kenudson, Mari ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 122, Boston, MA 02114 USA

[2] Harvard Med Sch, Boston, MA USA

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2017年 / 6卷 / 05期

关键词：

Anaplastic lymphoma kinase (ALK); proto-oncogene tyrosine-protein kinase ROS (ROS1); programmed death-ligand 1 (PD-L1); immunohistochemistry (IHC); predictive biomarker; non-small cell lung cancer (NSCLC); ANAPLASTIC-LYMPHOMA-KINASE; DEATH-LIGAND; IN-SITU-HYBRIDIZATION; ALK GENE REARRANGEMENT; PD-L1; EXPRESSION; ROS1; REARRANGEMENTS; SQUAMOUS-CELL; DIAGNOSTIC-VALUE; EGFR MUTATIONS; ANTIBODY; 1A4;

D O I：

10.21037/tlcr.2017.07.06

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the era of targeted therapy, predictive biomarker testing has become increasingly important for non-small cell lung cancer. Of multiple predictive biomarker testing methods, immunohistochemistry (IHC) is widely available and technically less challenging, can provide clinically meaningful results with a rapid turn-around-time and is more cost efficient than molecular platforms. In fact, several IHC assays for predictive biomarkers have already been implemented in routine pathology practice. In this review, we will discuss: (I) the details of anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) IHC assays including the performance of multiple antibody clones, pros and cons of IHC platforms and various scoring systems to design an optimal algorithm for predictive biomarker testing; (II) issues associated with programmed death-ligand 1 (PD-L1) IHC assays; (III) appropriate pre-analytical tissue handling and selection of optimal tissue samples for predictive biomarker IHC.

引用

页码：570 / 587

页数：18

共 127 条

[1] The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer [J].

Acquaviva, Jaime ;

Wong, Ricky ;

Charest, Al .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1795 (01) :37-52

[2] Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC [J].

Adam, Julien ;

Rouquette, Isabelle ;

Damotte, Diane ;

Badoual, Cecile ;

Danel, Claire ;

Damiola, Francesca ;

Penault-Llorca, Frederique ;

Lantuejoul, Sylvie .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S11-S12

[3] ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers [J].

Ali, Greta ;

Proietti, Agnese ;

Pelliccioni, Serena ;

Niccoli, Cristina ;

Lupi, Cristiana ;

Sensi, Elisa ;

Giannini, Riccardo ;

Borrelli, Nicla ;

Menghi, Maura ;

Chella, Antonio ;

Ribechini, Alessandro ;

Cappuzzo, Federico ;

Melfi, Franca ;

Lucchi, Marco ;

Mussi, Alfredo ;

Fontanini, Gabriella .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (11) :1449-1458

[4] PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC [J].

Ameratunga, Malaka ;

Asadi, Khashayar ;

Lin, Xihui ;

Walkiewicz, Marzena ;

Murone, Carmel ;

Knight, Simon ;

Mitchell, Paul ;

Boutros, Paul ;

John, Thomas .

PLOS ONE, 2016, 11 (04)

[5] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[6] Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project [J].

Blackhall, Fiona H. ;

Peters, Solange ;

Bubendorf, Lukas ;

Dafni, Urania ;

Kerr, Keith M. ;

Hager, Henrik ;

Soltermann, Alex ;

O'Byrne, Kenneth J. ;

Dooms, Christoph ;

Sejda, Aleksandra ;

Hernandez-Losa, Javier ;

Marchetti, Antonio ;

Savic, Spasenija ;

Tan, Qiang ;

Thunnissen, Erik ;

Speel, Ernst-Jan M. ;

Cheney, Richard ;

Nonaka, Daisuke ;

de Jong, Jeroen ;

Martorell, Miguel ;

Letovanec, Igor ;

Rosell, Rafael ;

Stahel, Rolf A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) :2780-+

[7]

Bledsoe JR, 2014, AM J SURG PATHOL, V38, P1418, DOI 10.1097/PAS.0000000000000263

[8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[9] ROS1 Immunohistochemistry Among Major Genotypes of Non-Small-Cell Lung Cancer [J].

Boyle, Theresa A. ;

Masago, Katsuhiro ;

Ellison, Kim E. ;

Yatabe, Yasushi ;

Hirsch, Fred R. .

CLINICAL LUNG CANCER, 2015, 16 (02) :106-111

[10] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

← 1 2 3 4 5 6 7 8 9 10 →